Last reviewed · How we verify
Tislelizumab and Bevacizumab
At a glance
| Generic name | Tislelizumab and Bevacizumab |
|---|---|
| Sponsor | Second Affiliated Hospital of Nanchang University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Aspartate aminotransferase increased
- Proteinuria
- Alanine aminotransferase increased
- Platelet count decreased
- Hypertension
- Rash
- Anaemia
- Pyrexia
- Pruritus
- COVID-19
- Hypoalbuminaemia
- Hyperuricaemia
Key clinical trials
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors (PHASE1)
- A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities (PHASE2)
- A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma (PHASE2)
- - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases (PHASE2)
- ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC (PHASE2)
- A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: